Premium Nahrungsergänzungsmittel | artgerecht

Enantiomeric Excess (ee) – Definition & Significance

Enantiomeric excess (ee) measures the purity of a chiral substance, indicating how much one enantiomer predominates over its mirror-image molecule in a mixture.

Regular tips about health Regular tips about health

Things worth knowing about "Enantiomeric excess"

Enantiomeric excess (ee) measures the purity of a chiral substance, indicating how much one enantiomer predominates over its mirror-image molecule in a mixture.

What Is Enantiomeric Excess?

Enantiomeric excess (abbreviated as ee) is a key measurement in stereochemistry and pharmaceutical chemistry. It describes the proportion of one enantiomer relative to its mirror-image counterpart in a given sample. An ee value of 100 % indicates that only one enantiomer is present (enantiopure substance), while an ee of 0 % corresponds to a racemic mixture – an equal distribution of both mirror-image forms.

This concept is especially important in medicine and pharmacology, as the two enantiomers of a drug molecule can have entirely different biological effects: one may be therapeutically active while the other is inactive or even harmful.

Fundamentals: Chiral Molecules and Enantiomers

Chiral molecules are molecules that exist as non-superimposable mirror images – much like a left and right hand. These mirror-image pairs are called enantiomers. They share the same molecular formula and most physical properties, but differ in the three-dimensional arrangement of their atoms (configuration).

Chiral structures play a central role in the human body: enzymes, receptors, and transport proteins are often highly selective for only one of the two mirror-image forms. This is why the specific enantiomer present in a drug can have major clinical consequences.

Definition and Calculation

Enantiomeric excess is calculated using the following formula:

ee (%) = |R − S| / (R + S) × 100

Here, R and S represent the percentage amounts of each enantiomer, named according to the CIP nomenclature (R for rectus, S for sinister). An ee value of 98 % is considered very high enantiopurity in pharmaceutical synthesis.

Importance in Pharmaceutical Chemistry

Controlling enantiomeric excess is critical in drug development. Many active pharmaceutical ingredients are manufactured either as a racemate (50:50 mixture of both enantiomers) or as an enantiopure compound. Regulatory authorities such as the EMA (European Medicines Agency) and the FDA (U.S. Food and Drug Administration) require detailed information on ee and stereochemical purity for new drug approvals.

Ibuprofen is sold as a racemate, although only the S-enantiomer has anti-inflammatory activity.
Esomeprazole is the pure S-enantiomer of omeprazole, developed as an improved formulation.
Thalidomide is a historically important example: the R-enantiomer had sedative properties, while the S-enantiomer was teratogenic (causing birth defects).

Methods of Measurement

Enantiomeric excess can be determined by several analytical techniques:

Chiral HPLC (High-Performance Liquid Chromatography): the most widely used method in pharmaceutical quality control.
Polarimetry: measurement of optical rotation of plane-polarized light by chiral substances.
NMR spectroscopy with chiral shift reagents.
Gas chromatography (GC) with chiral stationary phases.

Clinical Relevance

The concept of enantiomeric excess has direct clinical implications because:

One enantiomer may be therapeutically active while the other is inactive or toxic.
Enantiomers can have different half-lives and metabolic pathways in the body.
Enantiopure drugs often show improved tolerability and safety profiles.
The development of chiral switches – reformulating a racemate into its pure enantiomer – is an established strategy in drug development to improve efficacy and reduce side effects.

References

Clayden, J., Greeves, N., Warren, S. (2012): Organic Chemistry. Oxford University Press.
European Medicines Agency (EMA): Guideline on the Investigation of Chiral Active Substances. EMA/CHMP/ICH/764/1995.
Stinson, S. C. (2001): Chiral Pharmaceuticals. Chemical & Engineering News, 79(40), 79–97.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.